

A high-level summary of the quarterly pan-Canadian Pharmaceutical Alliance (pCPA) activity & processes

pCPA ACTIVITY



Initiated 27 files
(Q3 2022: 15 files)



Completed 15 files
(Q3 2022: 17 files)




Closed 3 files
(Q3 2022: 4 file)



Declined 4 files
(Q3 2022: 2 files)


FILES UNDER CONSIDERATION



Insights

- CADTH issued 16 positive and 4 'Do Not Reimburse' recommendations in Q4 2022.
- pCPA initiated negotiations for 27 files during the quarter. The volume of files under consideration decreased to 40 as of year end.
- The average days under consideration was fairly steady over the quarter, ending the year at 175 days.
- The quarterly average days under consideration was 165 days, continuing the downward trend seen in the previous quarter (193 days) and below the 2022 annual average of 178 days.

FILES UNDER NEGOTIATION




Insights


- pCPA initiated 27 files in Q4 2022 while it completed 15 and closed 3, resulting in a net increase in active negotiations.
- 5 of the files initiated during Q4 had negative CADTH recommendations but positive INESSS recommendations. All 5 had been under consideration for over 300 days, and 2 had been under consideration for over 2 years.
- The volume of oncology files under active negotiation reached its highest point of 2022 in December (22), while the volume of non-oncology files was at its lowest (14).
- The average time under negotiation decreased substantially to 105 days by year end. The quarterly average of 133 days was below the annual average timelines (158 days).
- Two negotiations were initiated and completed on the same day: Kirsty (insulin aspart), which had previously concluded without an LOI, and Keytruda (pembrolizumab) for adjuvant renal cell carcinoma.

pCPA CAPACITY

Volume of Processed Files



Long Term Files



Insights

- pCPA completed 15 negotiations (5 oncology, 5 non-oncology, and 5 "other") with LOIs in Q4 2022, closed 3 non-oncology negotiations, and declined to negotiate 4 files (2 oncology, 2 non-oncology).
- pCPA closed a total of 15 files without reaching an agreement in 2022, a higher volume than seen in recent years (8 files were closed in 2021, and 7 in 2020).
- 3 of the files that closed were later successfully negotiated with LOIs, each with a negotiation timeline of 3 days or less: Kirsty (insulin aspart) for Types 1 & 2 diabetes, Inqovi (decitabine-cedazuridine) for myelodysplastic syndromes, and Ruzurgi (amifampridine) for Lambert-Eaton myasthenic syndrome.
- 4 files were not negotiated, all of which had negative recommendations from CADTH. 1 file, Minjuvi (tafasitamab), had a positive recommendation with conditions from INESSS.
- The number of files under consideration for >6 months decreased to 11 from a year high of 13 in September, 2022. 7 files that had been under consideration for >6 months initiated negotiations, but 5 files under consideration surpassed the 6 month mark. 3 files under active negotiation for >12 months closed without LOIs in December, bringing the total down to 0.